Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876304 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Taisho Pharmaceutical Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00876304: Completed Phase 1 study of Schizophrenia, sponsored by Taisho Pharmaceutical Co..
NCT00876304 is a Phase 1 study of Schizophrenia that has completed, run by Taisho Pharmaceutical Co.. The registered enrollment target is 39 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00876304, a Phase 1 study of Schizophrenia, has completed, sponsored by Taisho Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-04802540
Study Locations (1)
California
- Pfizer Investigational Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00876304 record still lists
NCT00876304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00876304 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00876304 about?
NCT00876304 is a clinical study titled "Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
What is the current status of trial NCT00876304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2009-04. Estimated completion is 2009-09.
What conditions does trial NCT00876304 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00876304?
The interventions under investigation include: Placebo (DRUG), PF-04802540 (DRUG).
Who is sponsoring clinical trial NCT00876304?
This trial is sponsored by Taisho Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00876304 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00876304's enrollment target sits among peer trials
39 244th of 315 higher than 71 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia